CN102821769A - 替加环素用于治疗癌症的用途 - Google Patents

替加环素用于治疗癌症的用途 Download PDF

Info

Publication number
CN102821769A
CN102821769A CN201180013184XA CN201180013184A CN102821769A CN 102821769 A CN102821769 A CN 102821769A CN 201180013184X A CN201180013184X A CN 201180013184XA CN 201180013184 A CN201180013184 A CN 201180013184A CN 102821769 A CN102821769 A CN 102821769A
Authority
CN
China
Prior art keywords
cancer
cells
mitochondrial
glycylcycline
tigecycline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180013184XA
Other languages
English (en)
Chinese (zh)
Inventor
A·D·希梅尔
M·斯克提克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN102821769A publication Critical patent/CN102821769A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
CN201180013184XA 2010-03-10 2011-03-10 替加环素用于治疗癌症的用途 Pending CN102821769A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31241010P 2010-03-10 2010-03-10
US61/312,410 2010-03-10
PCT/CA2011/000258 WO2011109899A1 (en) 2010-03-10 2011-03-10 Use of tigecycline for treatment of cancer

Publications (1)

Publication Number Publication Date
CN102821769A true CN102821769A (zh) 2012-12-12

Family

ID=44562767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180013184XA Pending CN102821769A (zh) 2010-03-10 2011-03-10 替加环素用于治疗癌症的用途

Country Status (6)

Country Link
US (1) US20120329761A1 (enExample)
EP (1) EP2544692A4 (enExample)
JP (1) JP2013521314A (enExample)
CN (1) CN102821769A (enExample)
CA (1) CA2790240A1 (enExample)
WO (1) WO2011109899A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142624A (zh) * 2013-03-01 2013-06-12 西南大学 抗生素替加环素在制备抗癌药物中的应用
CN109331026A (zh) * 2018-04-21 2019-02-15 温州医科大学附属第医院 替加环素在制备抗多发性骨髓瘤药物中的应用
CN110167560A (zh) * 2016-08-30 2019-08-23 四相制药公司 四环素化合物和治疗方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013010256A1 (en) * 2011-07-15 2013-01-24 University Health Network Combination treatment for cancer
WO2014029016A1 (en) * 2012-08-24 2014-02-27 University Health Network Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer
AU2013308504B2 (en) 2012-08-31 2016-11-10 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
EP3696276A1 (en) 2013-02-25 2020-08-19 Novartis AG Novel androgen receptor mutation
US9937161B2 (en) 2013-03-06 2018-04-10 The General Hospital Corporation Combinatorial compositions and methods for treatment of melanoma
KR102880712B1 (ko) 2016-10-19 2025-11-03 테트라페이즈 파마슈티컬스, 인코포레이티드 에라바사이클린의 결정질 형태
CA3063717C (en) 2017-05-19 2021-08-24 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CA3102264A1 (en) * 2018-06-19 2019-12-26 Lunella Biotech, Inc. "energetic" cancer stem cells (e-cscs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064728A2 (en) * 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
CN1889957A (zh) * 2003-09-05 2007-01-03 惠氏公司 替加环素单独或与利福平联合治疗骨髓炎和/或脓毒性关节炎的应用
CN101228112A (zh) * 2005-05-27 2008-07-23 惠氏公司 替加环素及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
AU1763201A (en) * 1999-11-10 2001-06-06 Mitokor Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US20040253728A1 (en) * 2000-11-10 2004-12-16 Claes Gustafsson New method
EP1439843A4 (en) * 2001-10-05 2007-01-03 Tetragenex Pharmaceuticals Inc TETRACYCLINE DERIVATIVES AND METHODS OF USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064728A2 (en) * 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
CN1889957A (zh) * 2003-09-05 2007-01-03 惠氏公司 替加环素单独或与利福平联合治疗骨髓炎和/或脓毒性关节炎的应用
CN101228112A (zh) * 2005-05-27 2008-07-23 惠氏公司 替加环素及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COBY VAN DEN BOGERT,ET AL.: "Arrest of the Proliferation of Renal and Prostate Carcinomas of Human Origin by Inhibition of Mitochondrial Protein Synthesis", 《CANCER RESEARCH》, vol. 46, 31 July 1986 (1986-07-31), pages 3283 - 3289, XP055068666 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142624A (zh) * 2013-03-01 2013-06-12 西南大学 抗生素替加环素在制备抗癌药物中的应用
CN110167560A (zh) * 2016-08-30 2019-08-23 四相制药公司 四环素化合物和治疗方法
CN110167560B (zh) * 2016-08-30 2023-08-18 四相制药公司 四环素化合物和治疗方法
CN109331026A (zh) * 2018-04-21 2019-02-15 温州医科大学附属第医院 替加环素在制备抗多发性骨髓瘤药物中的应用

Also Published As

Publication number Publication date
WO2011109899A1 (en) 2011-09-15
EP2544692A4 (en) 2013-08-07
JP2013521314A (ja) 2013-06-10
EP2544692A1 (en) 2013-01-16
CA2790240A1 (en) 2011-09-15
US20120329761A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
CN102821769A (zh) 替加环素用于治疗癌症的用途
Castro-Muñoz et al. Modulating epigenetic modifications for cancer therapy
Feustel et al. Protein arginine methyltransferase 5 (PRMT5) inhibitors in oncology clinical trials: a review
Cerchietti et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
US11092602B2 (en) Methods and compositions relating to proteasome inhibitor resistance
KR20160132496A (ko) 초분자 조합 치료제
JP2014514326A (ja) 抗癌療法としての正常細胞および腫瘍細胞の小分子ｔｒａｉｌ遺伝子誘導
US20180353445A1 (en) Methods and compositions relating to proteasome inhibitor resistance
KR20240121720A (ko) 메닌-mll 후성유전학적 복합체 파괴에 의한 위장관 기질 종양(gist)의 치료 표적화
WO2022183006A1 (en) Compounds for programmable protein degradation and methods of use for the disease treatment
CN102791260A (zh) 低氧诱导因子抑制剂的用途
Li et al. KDM4 inhibitor SD49-7 attenuates leukemia stem cell via KDM4A/MDM2/p21CIP1 axis
WO2020198601A1 (en) Combinatorial drug treatment of cancer
US20140221301A1 (en) Combination treatment for cancer
CN103877069B (zh) 微RNA‑34a的小分子调节剂
EP2606909B1 (en) Method and composition for treating, preventing and diagnosing cancer containing cancer stem cells or derived therefrom
Al-Hamaly et al. The mitochondria as an emerging target of self-renewal in T-cell acute lymphoblastic leukemia
EP4516300A2 (en) Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
US20110212176A1 (en) Ciclopirox and cytarabine for the treatment of leukemic disorders
CA2849903A1 (en) Combination therapy for chemoresistant cancers
WO2024263933A1 (en) Compositions and methods for the treatment of cancers by triggering anti-viral response
WO2020172086A1 (en) Targeting lasp1, eif4a1, eif4b, and cxc4 with modulators and combinations thereof for cancer therapy
US20230115120A1 (en) Compositions, methods and uses of combination treatments for blood cancers
US20230391824A1 (en) Rationale, design, synthesis and validation of a small molecule anticancer agent
JP2021525809A (ja) プロドラッグおよびその医学的使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121212